TACE Plus Durvalumab and Bevacizumab Could Alter SOC in Embo

Riccardo Lencioni, MD, discusses how TACE, durvalumab, and bevacizumab, could represent a new standard of care in embolization-eligible HCC.

Related Keywords

Italy , Riccardo Lencioni , Department Of Surgery , Cancers Symposium , Critical Area Pathology , D , Chemoembolization Tace , Urvalumab Imfinzi , Nd Bevacizumab Avastin , Hepatocellular Carcinoma , Hcc , Phase 3 Emerald 1 Trial Nct03778957 ,